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Abstract
Objective and design The skin retention and penetration
characteristics of copper applied as glycyl-L-histidyl-L-
lysine cuprate diacetate were evaluated in vitro in order to
assess the potential for its transdermal delivery as anti-
inflammatory agent.
Materials and methods Flow-through diffusion cells with
1 cm2 exposure area were used under infinite dose condi-
tions. 0.68% aq. Copper as a tripeptide was applied on
isolated stratum corneum, on heat-separated epidermis and
on dermatomed skin. Receptor fluid collected over 48 h in
4 h intervals was analyzed by inductively coupled plasma
mass spectrometry for copper in tissues and receptor fluid.
Results The permeability coefficient of the compound
through dermatomed skin was 2.43 ± 0.51 9 10-4 cm/h;
136.2 ± 17.5 lg/cm2 copper permeated 1 cm2 of that tis-
sue over 48 h, while 82 ± 8.1 lg/cm2 of copper were
retained there as depot.
Conclusions Applied tansdermally as the tripeptide on
human skin ex vivo, copper permeated the skin and was
also retained in skin tissue in amounts potentially effective
for the treatment of inflammatory diseases.
Keywords Absorption  Arthritis  Bioavailability 
Copper complex  Depot  Inflammation
Introduction
Acute and chronic inflammation are characterized by
changes in the metabolism of copper and by a pronounced
responsiveness to therapy with copper compounds [1, 2].
The copper content and ceruloplasmin activity of serum are
significantly elevated above normal values in inflammatory
diseases in humans and laboratory animals, and copper in
widely different chemical forms is used as therapeutic
agent in therapy for chronic and acute inflammation [2].
The rise in total serum copper measured in inflammation is
held to represent the natural anti-inflammatory response of
the organism itself. The responsiveness of inflammatory
disorders to copper supplementation suggests that the
control exerted by endogenous copper on inflammation is
susceptible to enhancement by exogenous sources. When
copper complexes were administered subcutaneously in
experimentally inflamed animals the reduction in inflam-
mation was proportional to total amount of copper injected
[3].
While for nearly three-quarters of a century water sol-
uble gold salts have been administered for their anti-
inflammatory properties, most effective among them gold
thiomalate, particularly to relieve the symptoms of juvenile
and adult rheumatoid arthritis [4], just how the metal exerts
its anti-arthritic effect is not clear as it does not have a
known biological function itself. Also, since the inception
of systemic therapy using gold compounds the incidence of
allergic skin reactions to the metal has been remarkably
high, attributed to induced hypersensitivity [5]. However,
recently Stoyanov and Brown [6] attributed an indirect role
played by gold. They found that it specifically binds to a
copper-activating protein, thus turning on production of a
protein pump involved in copper transport thus mobilizing
endogenous copper reserves stored mostly in liver and
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muscle. The biological effect of gold anti arthritic drugs
may thereby consist in their effect on copper management
in eukaryotic systems.
We investigated possible transdermal dosing of copper
as the alternative to what so far has been the therapy for
inflammatory disorders relying on intra articular or intra
muscular injection of drugs which comports considerable
patient discomfort.
Data on human skin penetration by copper compounds
are scarce. The percutaneous absorption of copper from
copper chloride and copper sulfate were investigated in
vitro on human skin by Pirot et al. [7]. Formulated for
therapeutic purposes, the salts were compounded with zinc
chloride and zinc sulfate in petrolatum and two aqueous
gels. For both the apparent permeability coefficients Kp
were similar: 3.2–4.5 9 10-6 cm/h. Extensive investiga-
tions conducted over years by Pickart into the multiple
functions of the human tripeptide glycidyl-L-histidyl-L-
lysine as its copper 2? complex (GHK-Cu), recently
reviewed [8], made that molecule an obvious choice for our
skin penetration study.
Using a model membrane made of stratum corneum
lipids, Mazurowska had suggested that copper peptides,
and GHK-Cu in particular, might permeate skin [9].
However, experiments using skin models generally
underestimate absorption since the composition of model
membranes does not reflect the structure of the stratum
corneum, a heterogeneous, multi component membrane,
nor does it account for the high hydrophilicity of GHK-Cu
which may determine an idiosyncratic path of diffusion
[10, 11]. Orth [12] and Finkey [13] measured uptake of
copper into superficial facial skin strata in vivo when
applying GHK-Cu for cosmetic purposes, but to date bio-
availability of copper was not studied quantitatively using
human skin ex vivo. Therefore, evidence that copper does
penetrate the skin in any form is so far based on its
observed effects only: anti-inflammatory activity by topical
application of copper complexes was shown in animals by
Brown [1], by Sorenson in man [2], and has extensively
been reviewed by Milanino [14].
Materials and methods
Materials
The permeant was GHK-Cu (Ac)2, received from the
ProCyte Corp. (Kirkland, WA). It was not analyzed for
stoichiometric purity since, in several studies, copper
complexes in a physiological environment were subject to
de-complexation and rearrangement, depending on pH
and complex stability constants [15, 16]. Those investi-
gations indicated the presence of multiple species for
GHK-Cu (e.g., tri- and hexa-peptide) in solutions, toge-
ther with copper-free oligopeptide. Copper as a transition
metal of variable oxidation states has the ability to form
complexes with different geometries and stability. Here
the test compound is summarily referred to as GHK-Cu.
Concentrations are reported in terms of copper per ml of
solution.
Chemical: Glycyl-L-histidyl-L-lysine copper cuprate, diacetate GHK-
Cu (Ac)2, Formula: C18H29CuN6O8
Experimental design
In vitro (a.k.a. ex vivo) skin diffusion studies were con-
ducted with GHK-Cu at 0.68% aq. concentration using
glass cells to mimic in vivo permeant flux. Copper depot
formation and penetration was studied using:
Isolated stratum corneum (Experiment A)
Entire epidermis, including stratum corneum (experi-
ment B)
Split thickness skin comprising stratum corneum, epi-
dermis and underlying dermis tissue (experiment C)
Tissue preparation
Human cadaver skin was obtained from the Northern
California Transplant Bank (San Rafael, CA) and stored in
a freezer (-20C) until use. All experiments were per-
formed within 2 months after freezing. Subjects were 3
Caucasian, aged 21–53 years, and both genders were
represented.
Split thickness skin (entire epidermis with a portion of
the dermis) was obtained by use of a dermatome targeted to
500 lm and stored (-20C) until use.
Entire epidermis, (isolated epidermis including stratum
corneum), was obtained by heat separation (60C) from
underlying dermis tissue and stored (-20C) until use.
Isolated stratum corneum was obtained from isolated
epidermis which was placed on Whatman paper soaked in a
984 J. J. Hostynek et al.
0.05% w/w trypsin Type III (from bovine pancrease, Sigma
Chemical, St. Louis, USA) solution in 0.15 M phosphate
buffered saline (PBS, pH 7.4, Sigma) for 2 h at 37C.
Remaining trypsin activity was blocked by submerging the
stratum corneum sheet in 0.05% w/w trypsin inhibitor
Typed II (from soybean, Sigma Chemicals, St. Louis,
USA), then the stratum corneum sheet washed twice in
purified water, dried and stored above silica gel at room
temperature.
Diffusion experiment
Ex vivo skin tissue was obtained from three donors. Rep-
licates were run on tissue from the same donor. Glass low -
volume flow cells with 0.8 cm2 exposure area were kept at
37C. Receptor fluid was collected over 48 h in 4 h inter-
vals. Cells were mounted in the wells of aluminum cell
holder (Stratacor, Richmond, CA), whose internal channels
were perfused with water at 37C from a circulating water
bath, and holders mounted on a fraction collector. Distilled
water containing 1 ml/l of gentamicin sulfate solution
(l00 mg/ml, Sigma, St. Luis, MO) was pumped through the
cells at approximately 2 ml/h with a 12 channel peristaltic
pump. Tissues were cut into circles with a biopsy punch
(1 cm2), mounted on the diffusion cells and the donor
chambers clamped in place.
To test for tissue integrity, prior to the experiment with
tissue discs clasped in place the peristaltic pump was run at
10 rpm generating back pressure in the receptor cells (five
times the normal pressure) for 2 h to check for leakers,
which were eliminated.
About 1 ml of test solution was placed in the donor
chambers, closed with ground glass stoppers and sealed with
Parafilm to prevent donor solution evaporation. Eight cells
were typically set up at one time, with four cells used for
each of two treatments. Receptor fluid samples were col-
lected in a 20-ml polyethylene screw-cap scintillation (LSC)
vials (Maxi-vial, Packard Instruments, Downers Grove, IL).
At completion of an experiment the donor cell contents were
pipetted into LSC vials. The donor chamber and skin surface
was rinsed (3 9 2 ml) with distilled water and the rinse
saved in the LSC vials with polyethylene cap liners (Perkin-
Elmer, Shelton, CT). Nitric acid (0.75 g) was added to each
skin sample and the vial heated (50–60C) to effect disso-
lution. After cooling, samples were diluted with 15 ml
distilled water to give a final nitric acid concentration of
3.5% required for inductively coupled plasma mass spec-
troscopy analysis. Samples were filtered and stored at 4C.
Analytical methodology
For original copper levels, portions of isolated stratum
corneum, isolated epidermis, as well as split thickness
dermis were analyzed to determine the increment retained
there during diffusion. Following the diffusion experiment
C, split thickness skin was also separated into epidermis
and dermis (entire separated epidermis and separated der-
mis) for analysis of tissue depot formation in the
experiment.
Experimental details and results are reported in terms of
copper, analyzed by inductively coupled plasma mass
spectroscopy. It is a technique applicable to lg/l (ppb)
concentrations of many elements in aqueous medium upon
appropriate sample preparation of biological materials.
Reliability of the method for elemental analysis is based
upon multi-laboratory performance compared with that of
either furnace atomic absorption spectroscopy or ICP-AES.
Normal instrument detection limit for copper can be
anticipated at 0.5 ppb.
Inductively coupled plasma mass spectroscopy analyses
were performed by DuPont Analytical Solutions, Wil-
mington, DE. There samples were prepared by diluting
1:10 (volume/volume), using 2% HNO3 immediately prior
to analysis. The ICP-MS equipment used was an Agilent
7500c, operated under helium collision gas mode. The
instrumental detection limit was \100 pg/ml copper.
Standard solutions were prepared by diluting a 1,000-lg/ml
copper stock solution with 2% HNO3. Two separate (low
concentration and high concentration) six-point external
calibration curves (r2 [ 0.999) were used for quantitation
of both copper isotopes (63 and 65 Cu) with 89Y used as an
internal standard. The low concentration calibration curve
was constructed from 1, 2, 5, 10, and 20 ng/ml Cu stan-
dards and the high concentration calibration curve was
from 20, 100, 1,000, 5,000, and 10,000 ng/ml copper
standards. The instrument was calibrated using the five
standards above, and the samples bracketed between the
standards without extrapolation either below the calibration
curve nor above it.
Data analysis
The permeability coefficient Kp (cm/h) is the ratio of
steady state flux and the donor concentration multiplied by
the membrane area covered. The flux (lg/cm2/h) at steady
state (Jss) is the permeant value per membrane area per
hour following the initial lag time which is the delay
measured for the permeant to reach a constant value Jss.
The Kp was calculated from the permeation rate at steady
state flux Jss, determined from the linear portion of the
amount permeated versus time profile. The permeation
profile of copper for each tissue layer was plotted against
time.
The tissue copper levels reported from diffusion exper-
iments were corrected for endogenous levels determined
prior to the experiments.
Human skin retention and penetration 985
Results
Skin permeability coefficients (Kps) for the copper tri-
peptide ranged from 3 9 10-7 cm/h through isolated
epidermis (Table 1, Exp. B), to 5.59 9 10-3 cm/h through
isolated stratum corneum (Table 1, Exp. A).
Lag times measured from 2 h on isolated stratum cor-
neum and spilt thickness skin (Table 1, Exp. A, C), to 7 h
on isolated epidermis (Table 1, Exp. B).
Copper collected in the receptor fluid in 48 h ranged
from 0.60 ± 0.21 lg/cm2 or 0.006 ± 0.001% of the dose
through isolated epidermis (Exp. B; Table 2), to
136.2 ± 17.5 lg/cm2 or 2.0 ± 0.31% through split thick-
ness skin (Exp. C, Table 2).
About 290 ± 69 lg/cm2 Copper was retained in the
stratum corneum tissue, a 438-fold increase over baseline
levels (Table 3, Exp. A). Isolated epidermis retained
61.1 ± 13.1 lg/cm2, a factor of 165 over base line
(Table 3, Exp. B), and dermatomed skin 53 ± 8.1 lg/cm2
or 31 times baseline (Table 3, Exp. C).
Discussion
This study evaluates absorption and skin retention of a
copper tripeptide in separate skin compartments: the stra-
tum corneum, entire epidermis and split thickness skin.
The amount of copper deposited from the tripeptide in
the stratum corneum as well as in the entire epidermis and
dermis is significant. For instance, about a 400-fold
increase over baseline was retained in the isolated stratum
corneum. Such high tissue retention of copper may be
attributed to intradermal decomplexation and re-binding to
various endogenous amino acids of higher nucleophilic
donor capacity than the original ligand.
Assessing whether permeant retained in skin tissues, the
stratum corneum in particular, eventually becomes avail-
able systemically is an issue of ongoing discussions.
Reservoir formation in the course of in vitro studies has
been addressed [17]. Retained drug may be lost to natural
desquamation, limiting its eventual systemic availability.
On closer analysis, however, it has been found that the
Table 1 Copper skin penetration as function of skin strata from aq.
GHK-Cu solution. Skin permeability coefficients (Kp), steady-state
skin penetration flux and lag time for copper tripeptide are shown for
isolated stratum corneum, total epidermis and split thickness
(dermatomed) human skin, respectively
Exp. Skin strata Kp 9 104 (cm/h) ± SD Flux (lg/cm2/h) ± SD Lag time (h)
A Isolated stratum corneum (n = 3) 55.9 ± 13.2 38 ± 9 2
B Isolated epidermis (n = 3) 0.003 ± 0.0006 0.002 ± 0.0004 7
C Dermatomed skin (n = 8) 2.43 ± 0.51 1.7 ± 0.35 2
Difference in values were considered significant (P \ 0.05)
Table 2 Human skin retention and penetration of copper in function of skin strata
Exp. Skin strata Donor
recovered
Stratum
corneum
Total
epidermis
Dermatomed
skin
Receptor fluid Total %
recovered
A Isolated stratum corneum (n = 3) (79 ± 13) 290.3 ± 69 NA NA 2110 ± 589 (19.85 ± 3.9) (98 ± 27)
B Total epidermis (n = 3) (94 ± 12) ND 61.1 ± 13.1 NA 0.60 ± 0.21 (0.006 ± 0.001) (95 ± 12)
C Dermatomed skin (n = 8) (91 ± 14) ND ND 82 ± 8.1 136.2 ± 17.5 (2.0 ± 0.31) (94 ± 7)
Amount of copper found in the stratum corneum, total epidermis, dermatomed skin, receptor fluid, donor compartment as well as the total amount
recovered are given in lg per cm2 and in percentages of the applied copper dose (in brackets) after 48 h. Difference in values were considered
significant (P \ 0.05)
NA not applicable; ND not determined
Table 3 Copper reservoir in skin layers vs. original levels from 0.68% aq. GHK-Cu at 48 h
Skin compartment Cu at 0 h (lg/cm2) Cu at 48 h (lg/cm2) Increase vs. 0 h
Isolated stratum corneum (Exp. A) 0.68 ± 0.3; n = 3 290 ± 69; n = 3 4389
Total epidermis (Exp. B) 0.37 ± 0.2; n = 3 61.1 ± 13.1; n = 3 1659
Dermatomed skin (Exp. C) 1.72 ± 0.5; n = 8 53 ± 8.1; n = 8 319
Baseline copper levels and copper levels after 48 h exposure to 0.68% copper peptide solution are given for stratum corneum, total epidermis and
split thickness (dermatomed) skin. The difference in values were considered significant (P \ 0.05)
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fraction of chemical sloughing off versus the part that
becomes systemically available depends on the ratio of lag
time to the turnover time for the stratum corneum [18].
Accordingly, at least 80% of the amount in the stratum
corneum will become available if the lag time for pene-
tration through that tissue is less than approximately 16 h
This corresponds to 5% of the typical stratum corneum
turnover time of 14 days. Consequently, based on our
results where lag times ranged from 2 to 7 h, the copper
retained in the stratum corneum has the potential to
become systemically available also. As a result of the
experiment with dermatomed skin, by topical application
of GHK-Cu under the present conditions 200–250 lg/cm2
copper may become systemically available. Since the
experiment was conducted ex vivo, it is possible that even
larger amounts will be retained in the deeper dermal tissue
in vivo, to be followed by further diffusion.
The permeation rate of GHK-Cu through stratum cor-
neum seems high, the highest of all three skin strata
studied, consistent with a model of porous transport.
Appendageal penetration is considered to be one, if not the
predominant pathway for the diffusion of multipolar ions
[19, 20]. In addition, the high penetration level through
isolated stratum corneum can be attributed to the absence
of retention in underlying skin, which would limit copper
penetration.
The marked hydrophilicity of the copper tripeptide with
a pseudo logPow = -4.5, the quotient saturated n-octanol/
saturated aqueous solution [21], is reconcilable with shunt
penetration typical for highly hydrophilic solutes such as
salts. Significant penetration through appendages can occur
within minutes following exposure in contrast to non-
appendageal pathways [22, 23].
The Kps of GHK-Cu through epidermis and derma-
tomed skin were lower by about one order of magnitude.
Restriction of the pores area may be the cause for the
discrepancy in those diffusion constants when compared to
stratum corneum alone.
The present study indicates that topical administration of
copper as the tripeptide may offer an effective alternative
to injection. Since a realistic dimension for topical appli-
cation of GHK-Cu as a patch may cover 10 cm2 of skin,
based on our results 1.36 mg of copper would then become
available over 48 h.
When administering copper for therapeutic purposes, the
potential for toxicity should be considered. There is ample
evidence that the copper ion released will be subject to the
highly efficient homeostatic control in eukaryotic organ-
isms, preventing its circulation at toxic levels. Free ionic
copper, a relatively toxic metal, is moderated to the mini-
mum levels sufficient for physiological needs, reported in
the range of 10-11 to 10-19 mol estimated in plasma, by
binding to ceruloplasmin and metallothionein [24]. The
dynamic equilibrium between ceruloplasmin and metallo-
thionein stored in liver tissue prevents toxic accumulation
of free copper ion in mammals [25]. That hepatic reservoir
is released slowly back into the blood as ceruloplasmin and
copper metallothionein in response to inflammation due to
injury or arthritis [26]. The average level of bound copper
in human control plasma is 1.12 lg/ml [27]; in arthritic
patients it is 1.40 lg/ml [28]. A therapeutically effective
copper level in inflammation cannot be assessed in definite
terms, however, because copper status induced in response
to inflammatory diseases in humans varies depending on
target organ [14]. In order to document the tolerability of
metallic copper in contact with the skin, which must first be
oxidized in order to penetrate, Gorter examined absorption
and tolerance of metallic copper-containing ointments on
human volunteers over a period of several weeks. Copper
analysis in serum showed that levels had increased sig-
nificantly above control levels, without overt untoward
effects, either in the skin or systemically, following
application of ointments containing up to 20% of the metal
in its elemental form [29].
Conclusions
The results obtained show that a topical organic copper
complex such as GHK-Cu may be an alternative to copper
delivery by injection, also potentially providing a skin
reservoir likely to become available over time. This effect
warrants further development toward transdermal delivery
of the anti-inflammatory agent, especially when consider-
ing GHK as ligand, a nature identical carrier tripeptide [8].
In the past, several laboratories demonstrated local and
systemic anti-inflammatory activity of copper compounds
by oral, ip, iv, and particularly subcutaneous administra-
tion. Having shown permeation of the skin barrier by
GHK-Cu in a therapeutically effective dose, however,
application of this principle to transdermal dosing may now
offer a realistic alternative to current, traditional thera-
peutic routes and agents. Taking our results a step further,
one can optimize the controlled release of copper for anti-
inflammatory therapy using patch technology with
well-designed formulations. This would present a welcome
alternative to current methods, which rely on corticoste-
roids, NSAIDs, chrysotherapy, or the family of COX-2
cyclooxygenase inhibitors as analgesics and anti-inflam-
matory agents, since most of them are associated with
untoward side effects [30–32], some of them causing
considerable discomfort, depending on the mode of
administration.
That a deficit in this essential element may be substan-
tially corrected by choosing an appropriate cupriphore
represents a significant outcome of our endeavors towards
Human skin retention and penetration 987
alleviating rheumatoid arthritis and similar musculoskeletal
conditions afflicting the general population.
Acknowledgments We express our appreciation for the guidance
received from the late Roberto Milanino, MD, of the University of
Verona, who brought insight into the biological relevance of our
research and to whose memory we dedicate this manuscript. We thank
Len Patt of the ProCyte Corporation (Redmond, WA) for making a
complimentary sample of the copper tripeptide available for our
investigation. We thank Larry Ryan, DuPont Analytical Solutions
(Wilmington, DE) for supervising inductively coupled plasma mass
spectroscopy analyses, and Jeannette Woodward for their execution.
No external funding was involved in the pursuit of this research.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Brown DH, Smith WE, Teape JW, Lewis AJ. Anti-inflammatory
effects of some copper complexes. J Med Chem. 1980;23:
729–34.
2. Sorenson JRJ. Copper chelates as possible active forms of the
antiarthritic agents. J Med Chem. 1979;19:135–48.
3. Jackson GE, Mkhonta-Gama L, Voye A, Kelly M. Design of
copper-based anti-inflammatory drugs. J Inorg Biochem.
2000;79:147–52.
4. Browning JS, Rice RM, Lee WV, Baker LM. Gold therapy in
rheumatoid arthritis. N Engl J Med. 1947;237:428–31.
5. Hostynek JJ. Gold: an allergen of growing significance. Food
Chem Toxicol. 1997;35(8):835–44.
6. Stoyanov JV, Brown NL. The escherichia Coli copper-responsive
copA promoter is activated by gold. J Biol Chem. 2005;278:1407.
7. Pirot F, Millet J, Kalia YN, Humbert P. In vitro study of percu-
taneous absorption, cutaneous bioavailability and bioequivalence
of zinc and copper from five topical formulations. Skin Phar-
macol. 1996;9:259–69.
8. Pickart L. The human tripeptide GHK (Glycyl-L-Histidyl-L-
Lysine). T he copper switch, and the treatment of degenerative
conditions of aging. Anti-Aging Therapeutics vol. XI. 2009;
301–312.
9. Mazurowska L, Nowak-Buciak K, Mojski M. ESI-MS study of
the mechanism of glycyl-L-histidyl-L-lysine-Cu(II) complex
transport through model membranes of stratum corneum. Talanta.
2007;72:650–4.
10. Schaefer H, Redelmeier TE. Permeability properties of the stra-
tum corneum. In: Skin barrier. Principles of percutaneous
absorption. New York: Karger; 1996. pp. 87–117.
11. Schaefer H, Lademann J. The role of follicular penetration—a
differential view. Skin Pharmacol Appl Physiol. 2001;14(Suppl 1):
23–7.
12. Orth DS, Widjaja J, Ly L, Cao N, Shapiro WB. Stability of skin
persistence of topical products. Cosmet Toilet. 1998;113:51–63.
13. Finkey M, Appa Y, Bhandarkar S. Copper peptide and skin. In:
Elsner P, Maibach HI, editors. Cosmeceutical and active cos-
metics. New York: Taylor and Francis; 2005. p. 550–64.
14. Milanino R, Buchner V. Copper: role of the endogenous and
exogenous metal on the development and control of inflammatory
processes. Rev Environ Health. 2006;21:153–215.
15. Freedman JH, Pickart L, Weinstein B, Mims WB, Peisach J.
Structure of the glycidyl-L-histidyl-L-lysine-copper(II) complex
in solution. Biochemistry. 1982;21:4540–4.
16. Conato C, Gavioli R, Guerrini R, Kozlowski H, Mlynarz P, Pasti
C, Pulidori F, Remelli M. Copper complexes of glycyl-histidyl-
lysine and two of its synthetic analogues: chemical behaviour
and biological activity. Biochim Biophys Acta. 2001;1526:
199–210.
17. Yourick JJ, Koenig ML, Yourick DL, Bronaugh RI. Fate of
chemicals in skin after dermal application: does the in vitro skin
reservoir affect the estimate of systemic absorption? Toxicol
Appl Pharmacol. 2004;195:309–20.
18. Reddy MB, Bunge AL. In: Bronaugh RL, Maibach HI, editors.
Percutaneous absorption, 4th edn. New York: Marcel Dekker;
2005. pp. 165–176.
19. Potts RO, Guy RH, Francoeur ML. Routes of ionic permeability
through mammalian skin. Solid State Ionics. 1992;53–56:
165–9.
20. Mazzenga GC, Berner B, Jordan F. The transdermal delivery of
zwitterionic drugs II: the flux of zwitterionic salts. J Contr Rel.
1992;20:163–70.
21. RCC. Determination of the partition coefficient (n-octanol/water)
of copper tripeptide-1 (PC 1044). RCC Ltd, Environmental
Chemistry & Parmaceutical Division; CH-4452 Ittingen/Swit-
zerland; 2002.
22. Sznitowska M, Berner B, Maibach HI. Percutaneous penetration
of multipolar ions: evidence for porous transport. Int J Pharm.
1995;123:41–5.
23. Lademann J, Otberg N, Richter H, Jacobi U, Schaefer H, Blume-
Peytavi U. Folliculaere Penetration—Ein entscheidender Pene-
trationsweg von topisch applizierten Substanzen. Hautarzt.
2003;54:321–3.
24. Furnival C, May PM, Williams DR. Models of low-molecular-
weight copper(II) complexing equilibria in relation to rheumatoid
arthritis. In: Rainsford KD, Brune K, Whitehouse MW, editors.
Trace elements in the pathogenesis and treatment of inflamma-
tion. Basel: Birkha¨user Verlag; 1981. pp. 241–257.
25. Cousins RJ. Absorption, transport, and hepatic metabolism of
copper and zinc: special reference to metallothionein and ceru-
loplasmin. Physiol Rev. 1985;65:238–309.
26. Powanda MC. Systemic alterations in metal metabolism during
inflammation as part of an integrated response to inflammation.
Agents Actions 1981;Suppl 8:121–135.
27. Iyengar GV, Kollmer WE, Bowen HJM. The elemental compo-
sition of human tissues and body fluids. New York: Verlag
Chemie; 1978.
28. Milanino R, Frigo A, Bamabara LM, Marrella M, Moretti U,
Pasqualicchio M. Copper and zinc status in rheumatoid arthritis:
studies on plasma, erythrocytes and urine, and relationship with
disease activity markers and pharmacological treatment. Clin Exp
Rheumatol. 1993;11:271–81.
29. Gorter RW, Butorac M, Cobian EP. Examination of the cutane-
ous absorption of copper after the use of copper-containing
ointments. Am J Ther. 2004;11:453–8.
30. Wallace JL, Muscara MN. Selective cyclo-oxygenase-2 inhibi-
tors: cardiovascular and gastrointestinal toxicity. Dig Liver Dis.
2001;33(Suppl 2S):21–8.
31. Szabo S, Spill WF, Rainsford KD. Non-steroidal anti-inflamma-
tory drug-induced gastropathy. Mechanism and management.
Med Toxicol Adverse Drug Exp. 1999;4:77–94.
32. Muscara MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN,
Asfaha S, Wallace JL. Selective cyclo-oxygenase-2 inhibition
with celecoxib elevates blood pressure and promotes leukocyte
adherence. Br J Pharmacol. 2000;129:1423–30.
988 J. J. Hostynek et al.
